Speech-Language Pathologists in Atlanta, TX Accepting Medicare
6 Speech-Language Pathologists found. Showing 1 - 6
 Mrs. Rachel Janeen Heldt, SLP/CCC Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 106 W Main St, Atlanta, TX 75551 Phone: 903-796-4194 |
Pamela Jane Pruitt Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 570 Texas Highway 43, Atlanta, TX 75551 Phone: 903-824-0508 |
Megan Michelle Farmer, MS CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2410 County Road 3437, Atlanta, TX 75551 Phone: 903-748-8073 |
Cynthia Womack Flint, M.S. CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 106 W Main St, Atlanta, TX 75551 Phone: 903-796-4194 |
Wynette C Betts, MS CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 505 Rabbit Blvd, Atlanta, TX 75551 Phone: 903-796-8115 Fax: 903-799-1014 |
Mrs. Glenna B Frost, MCD CCC SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1001 West Main Street, Atlanta, TX 75551 Phone: 903-796-8255 Fax: 903-796-6968 |
News Archive
U.S. panel may re-evaluate bird flu research after scientists present new data about risks to humans
Speaking at the American Society for Microbiology's (ASM) Biodefense and Emerging Diseases Research meeting in Washington, D.C., on Wednesday, Ron Fouchier, the leader of the team at Erasmus Medical Center in the Netherlands that genetically altered the H5N1 bird flu virus, making it transmissible among ferrets and "touching off public fears of a pandemic, said that the virus he created was neither as contagious nor as dangerous as people had been led to believe, prompting the United States government to ask that the experiments be re-evaluated by a government advisory panel that recommended in December that certain details of the work be kept secret and not published," the New York Times reports.
Ferring announces availability of LYSTEDA for cyclic heavy menstrual bleeding in U.S.
Ferring Pharmaceuticals Inc. announced today the U.S. commercial availability of LYSTEDA™ (tranexamic acid) tablets, the only non-hormonal and non-surgical therapy indicated specifically for the treatment of women with cyclic heavy menstrual bleeding (HMB). In clinical studies, LYSTEDA significantly reduced menstrual blood loss (MBL) over three and six cycles of use with the reduction seen as early as the first cycle of use.
Health law program may benefit early retirees, big firms
A health law program that will go into effect next month will steer $5 billion to buttress employer-sponsored health plans for retirees who are not yet old enough to qualify for Medicare and have no other options for buying coverage, The Associated Press reports.
Heart failure patients receiving LVAD may benefit from injection of powerful cells directly into heart
A multicenter team of researchers within the NIH-funded Cardiothoracic Surgical Trials Network, led by Icahn School of Medicine at Mount Sinai, have found end-stage heart failure patients who receive a surgically implanted left ventricular assist device heart pump may also benefit from a single dose of millions of powerful cells injected directly into their heart during surgery.
› Verified 1 days ago